Document:

Common Stock Transfer Agreement

 Exhibit 10.3 
 COMMON STOCK TRANSFER AGREEMENT 
 THIS COMMON STOCK TRANSFER AGREEMENT (this
“Agreement”) is made as of this 31st day of March, 2006, by and among Calando Pharmaceuticals Inc., a Delaware corporation (the “Company”), Arrowhead Research Corporation, a Delaware corporation
(“Investor”), and those individuals set forth on Schedule A attached hereto (each a “Stockholder” and collectively, the “Stockholders”). Capitalized terms used herein
which are not defined shall have the meanings ascribed to such terms in the Series A Purchase Agreement (as defined below). 
 RECITALS

 WHEREAS, the Company and Investor have entered into that certain Series A Preferred Stock Purchase Agreement of even date
herewith (the “Series A Purchase Agreement”), pursuant to which Investor will purchase shares of the Company’s Series A Preferred Stock; 
 WHEREAS, certain of the obligations of the parties to the Series A Purchase Agreement are conditioned upon the execution and delivery of this Agreement; 
 WHEREAS, the Stockholders acquired their shares of the Company’s Common Stock (“Common Stock”) pursuant to that
certain Stock Purchase Agreement dated February 10, 2005 between the Company and certain Stockholders, as amended by that certain Amendment to Warrant and Stock Purchase Agreement dated February 28, 2005 between the Company and the Mark E.
Davis and Mary P. Davis Living Trust Dated September 20, 1995, and as amended by that certain Amendment to Warrant and Stock Purchase Agreement dated February 28, 2005 between the Company and the John G. Petrovich and Rebecca J. Petrovich
Revocable Trust Dated August 31, 2000 (collectively, the “Purchase Agreements”). The Purchase Agreements each contain a right of first refusal exercisable by the Company in connection with any proposed transfer of the
shares acquired pursuant to such agreements (the “Refusal Rights”); and 
 WHEREAS, the parties to this
Agreement have reached certain agreements and understandings with respect to the sale and transfer of certain shares of Common Stock now held by each Stockholder to Investor in exchange for cash and/or Common Stock of Investor as further described
below. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the foregoing and the promises and covenants contained herein, the sufficiency of which is hereby acknowledged, all parties hereto agree as follows: 
 A. TRANSFER OF SHARES 
 1. The Shares. Subject to the terms and conditions herein contained, the Stockholders agree to transfer to the Investor at the Closing that number of shares of Common Stock of the Company set forth opposite each
Stockholder’s name on Schedule A attached hereto (the “Calando Shares”), and Investor agrees to purchase such Calando Shares at a purchase price equal to $2.00 per share (the “Purchase
Price”). The Purchase Price shall be payable as follows: 
 (a) For all Stockholders, one-third (1.3) of the
Purchase Price shall be payable in cash (by check or wire transfer) and two-thirds (2/3) of the Purchase Price shall be payable in shares of Common Stock of Investor (“ARC Shares”). 

 (b) For purposes of determining number of ARC Shares issuable as payment of Purchase
Price, an ARC Share shall be valued based on the average of the closing prices of the Common Stock of Investor during the last ten trading days prior to the Closing. 
 (c) The aggregate Purchase Price payable to each Stockholder and the form of payment is set forth in Schedule A. 
 2. Closing. The transfer of the Calando Shares hereunder shall take place at the offices of Dorsey & Whitney LLP,
38 Technology Drive, Irvine, California, 92618, at 1:00 P.M. on March 31, 2006, or at such other time and place as the Company, the Stockholders and Investor mutually agree upon orally or in writing (which time and place are designated as the
“Closing”). At the Closing, the Stockholders shall deliver to Investor certificates representing the Calando Shares duly endorsed for transfer, and Investor shall deliver to the Stockholders the cash portion of the Purchase
Price for such shares (by check or wire transfer), and Investor shall concurrently authorize its transfer agent to issue stock certificates registered in the name of each Stockholder receiving ARC Shares, representing the number of ARC Shares such
Stockholder is entitled to receive as set forth on Schedule A hereto. 
 3. Transfer/Waiver. The Company
hereby waives it Refusal Rights with respect to the transfer of the Calando Shares to Investor and consents to such transfer, and the Company hereby agrees that, notwithstanding any contrary provision in the Purchase Agreements, the Calando Shares
transferred to Investor shall no longer be subject to the terms and conditions of such Purchase Agreements. Nothing herein shall be deemed to be a waiver by the Company of the Refusal Rights (or any other rights) it may have with respect to any
other shares held by any Stockholders pursuant to the Purchase Agreements or otherwise. 
 B. REPRESENTATIONS AND WARRANTIES OF
INVESTOR 
 Investor hereby represents, warrants and covenants that: 
 1. Authorization. Investor has full power and authority to enter into this Agreement, and such agreement constitutes its
valid and legally binding obligation, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’
rights generally and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 
 2. Accredited Investor. Investor is an “accredited investor” within the meaning of the SEC Rule 501 of Regulation D, as presently in effect. 
  

 2 

 3. Restricted Securities. Investor understands that the Calando Shares it
is purchasing are characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired in a transaction not involving a public offering and that under such laws and applicable regulations such
Calando Shares may be resold without registration under the Securities Act of 1933, as amended (the “Act”), only in certain limited circumstances. In the absence of an effective registration statement covering the Calando
Shares or an available exemption from registration under the Act, the Calando Shares must be held indefinitely. 
 4.
Purchase for Own Account. The Calando Shares are being acquired for investment for Investor’s own account, not as a nominee or agent, and not with a view to the public resale or distribution thereof within the meaning of the Act.

 5. Investment Experience. Investor understands that the purchase of the Calando Shares involves substantial
risk. Investor has experience as an investor in securities of companies and acknowledges that (i) it can bear the economic risk of its investment in the Calando Shares and can bear the risk of holding the Calando Shares for an indefinite period
of time and (ii) it has such knowledge, sophistication and experience in financial or business matters that it is capable of evaluating the merits and risks of this investment in the Calando Shares and protecting its own interests in connection
with this investment. 
 6. Legends. It is understood that the certificates evidencing the Calando Shares may
bear a legend in substantially the following form (in addition to any legends required by applicable laws): 
 “These
securities have not been registered under the Securities Act of 1933, as amended. They may not be sold, offered for sale, pledged or hypothecated in the absence of a registration statement in effect with respect to the securities under such Act or
an opinion of counsel satisfactory to the Company that such registration is not required or unless sold pursuant to Rule 144 of such Act.” 
 7. ARC Shares. The ARC Shares will be, when issued in accordance with the terms of this Agreement, duly authorized, validly issued, fully paid and non-assessable shares. 
 C. REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS 
 Each Stockholder hereby represents, warrants and covenants that: 
 1. Authorization. Stockholder has full power and authority to enter into this Agreement, and such agreement constitutes its
valid and legally binding obligation, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’
rights generally and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 
 2. Ownership of the Shares. Such Stockholder is the sole owner of the Calando Shares it is selling pursuant to this Agreement and has full power and authority to convey such shares free and clear of all
liens, encumbrances, restrictions and claims of every 

  

 3 

 
kind and, upon delivery of and payment for such shares as herein provided, Investor will acquire good and valid title thereto, free and clear of all liens,
encumbrances, restrictions and claims of every kind. Except as provided in any applicable Purchase Agreement, there is no outstanding subscription, warrant, call, commitment, option or other agreement or right of any kind to purchase or otherwise to
receive or acquire from Stockholder any interest in such Calando Shares. 
 3. Accredited Investor. Stockholder
is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D, as presently in effect. 
 4.
Purchase for Own Account. The ARC Shares are being acquired for investment for such Stockholder’s own account, not as a nominee or agent, and not with a view to the public resale or distribution thereof within the meaning of the
Act. 
 5. Investment Experience. Such Stockholder understands that the purchase of the ARC Shares involves
substantial risk. Such Stockholder has experience as an investor in securities of companies and acknowledges that (i) it can bear the economic risk of its investment in the ARC Shares and can bear the risk of holding the ARC Shares for an
indefinite period of time and (ii) it has such knowledge, sophistication and experience in financial or business matters that it is capable of evaluating the merits and risks of this investment in the ARC Shares and protecting its own interests
in connection with this investment. 
 6. Reliance Upon Stockholder’s Representations. The Stockholder
understands and acknowledges that the offer, issuance and sale of the ARC Shares to it will not be registered under the Securities Act on the ground that such offer, issuance and sale will be exempt from registration under the Securities Act
pursuant to Regulation D thereunder and Section 4(2) thereof, and that Investor’s reliance on such exemption is based on the accuracy and truthfulness of each Stockholder’s representations set forth herein. 
 7. Receipt of Information. Stockholder acknowledges it has received from Investor or obtained independently, and has
carefully reviewed, copies of the SEC Documents. Stockholder has had an opportunity to ask questions and receive answers from Investor regarding the terms and conditions of the issuance and sale of the ARC Shares and the business, properties,
prospects and financial condition of Investor and to obtain any additional information requested and has received and considered all information it deems relevant to make an informed decision to purchase the ARC Shares. The “SEC
Documents” consist of Form 10-KSB for the fiscal year ended September 30, 2005, Form 10-Q for the quarterly period ended December 31, 2005, Form 8-K filed as of January 18, 2006, Form 8-K filed as of January 24,
2006, Form 8-K filed as of February 28, 2006 and Schedule 14A filed as of January 18, 2006. Stockholder further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the business,
properties, prospects and financial condition of the Company and to obtain any additional information requested and has received and considered all information it deems relevant to make an informed decision to sell its Calando Shares. 
 8. Restricted Securities. Stockholder understands that the ARC Shares it is purchasing are characterized as “restricted
securities” under the federal securities laws inasmuch as they are being acquired from Investor in a transaction not involving a public offering and that 

  

 4 

 
under such laws and applicable regulations such ARC Shares may be resold without registration under the Act only in certain limited circumstances. In the
absence of an effective registration statement covering the ARC Shares or an available exemption from registration under the Act, the ARC Shares must be held indefinitely. In addition, Stockholder agrees that Investor may place stop transfer orders
with its transfer agents with respect to such certificates in order to implement the restrictions on transfer set forth in this Agreement. 
 9. Legends. It is understood that the certificates evidencing the ARC Shares may bear a legend in substantially the following form (in addition to any legends required by applicable laws): 
 “These securities have not been registered under the Securities Act of 1933, as amended. They may not be sold, offered for sale,
pledged or hypothecated in the absence of a registration statement in effect with respect to the securities under such Act or an opinion of counsel satisfactory to the Company that such registration is not required or unless sold pursuant to Rule
144 of such Act.” 
 10. Tax Advisors. Stockholder has reviewed with Stockholder’s own tax advisors
the federal, state and local tax consequences of the sale of Calando Shares for cash and/or ARC Shares pursuant to this Agreement, and the transactions contemplated by this Agreement. Stockholder is relying solely on such advisors and not on any
statements or representations of Investor, the Company or any of their agents and understands that Stockholder (and not Investor or the Company) shall be responsible for its own tax liability that may arise as a result of the sale of Calando Shares
and the transactions contemplated by this Agreement. Stockholder represents that it has never been notified by the Internal Revenue Service that it is subject to 20% backup withholding. 
 11. Stockholder Counsel. Stockholder acknowledges that Stockholder has had the opportunity to review this Agreement, the
exhibits and the schedules attached hereto and the transactions contemplated by this Agreement with Stockholder’s own legal counsel. Stockholder is relying solely on Stockholder’s legal counsel and not on any statements or representations
of the Company, Investor or their agents or counsel for legal advice with respect to the sale of Calando Shares or the transactions contemplated by this Agreement. 
 D. PIGGY-BACK REGISTRATION RIGHTS 
 1. Arrowhead Registration. If
Investor proposes to register (including for this purpose a registration effected by Investor for stockholders other than the Stockholders) any of its common stock under the Act in connection with the public offering of such securities solely for
cash (other than a registration statement relating either to the sale of securities to employees of Investor pursuant to a stock option, stock purchase or similar plan or an SEC Rule 145 transaction, a registration on any form which does not include
substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities or a registration in which the only common stock being registered is common stock issuable upon
conversion of debt securities which are also being registered), Investor shall, at such time, promptly give each Stockholder written notice of such registration. Upon the written request of each Stockholder given within twenty (20) days after
mailing of such 

  

 5 

 
notice by Investor, Investor shall, subject to the provisions of Section D.3, cause to be registered under the Act all of the Registrable Securities
that each such Stockholder has requested to be registered. Investor shall have the right to terminate or withdraw any registration initiated by it under this Section D.1 prior to the effectiveness of such registration whether or not any
Stockholder has elected to include securities in such registration. For purposes hereof, “Registrable Securities” means the ARC Shares issued to the Stockholders pursuant to this Agreement and any common stock of Investor
issued as a dividend or other distribution with respect to, or in exchange for or in replacement of such ARC Shares. 
 2.
Expenses of Registration. Investor shall bear and pay all expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to the registrations pursuant to Section D.1 hereof,
including (without limitation) all registration, filing, and qualification fees, printers and accounting fees relating or apportionable thereto and the fees and disbursements (not to exceed $5,000) of one counsel for the selling Stockholders
selected by them, but excluding underwriting discounts and commissions relating to the Registrable Securities. 
 3.
Underwriting Requirements. In connection with any offering involving an underwriting of shares of Investor’s capital stock pursuant to Section D.1, Investor shall not be required to include any of the Stockholders’
securities in such underwriting unless they accept the terms of the underwriting as agreed upon between Investor and its underwriters, and then only in such quantity as the underwriters determine in their sole discretion will not jeopardize the
success of the offering by Investor, subject to the limitations set forth below. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities to be
sold other than by Investor that the underwriters determine in their reasonable discretion is compatible with the success of the offering, then Investor shall be required to include in the offering only that number of such securities, including
Registrable Securities, which the underwriters and Investor determine in their sole discretion will not jeopardize the success of the offering. In no event shall any Registrable Securities be excluded from such offering unless all other
stockholders’ securities have been first excluded. In the event that the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that
are included in such offering shall be apportioned pro rata among the selling Stockholders based on the number of Registrable Securities held by all selling Stockholders or in such other proportions as all selling Stockholders shall mutually be
agree. Notwithstanding the foregoing, in no event shall the amount of securities of the selling Stockholders included in the offering be reduced below twenty percent (20%) of the total amount of securities included in such offering. For
purposes of the preceding parenthetical concerning apportionment, for any selling stockholder which is a Stockholder of Registrable Securities and which is an investment fund, partnership, limited liability company or corporation, the partners,
members, retired partners, retired members, stockholders and affiliates of such Stockholder, or the estates and family members of any such partners, retired partners, members and retired members and any trusts for the benefit of any of the foregoing
persons shall be deemed to be a single “selling Stockholder”, and any pro-rata reduction with respect to such “selling Stockholder” shall be based upon the aggregate amount of shares carrying registration rights owned by all
entities and individuals included in such “selling Stockholder,” as defined in this sentence. 
  

 6 

 4. Termination of Registration Rights. The right of any Stockholder to
exercise any right provided for in this Section D, including the right to request inclusion in a registration, shall terminate on such date as all shares of Registrable Securities held by such Stockholder may immediately be sold under Rule 144
during any 90-day period. 
 E. MISCELLANEOUS PROVISIONS 
 1. Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party, other than the parties hereto or their respective successors and assigns,
any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 2. Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents entered into and to be performed entirely
within California. 
 3. Titles and Subtitles. The titles and subtitles used in this Agreement are used for
convenience only and are not to be considered in construing or interpreting this Agreement. 
 4. Notices. All
notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed telex or facsimile if sent during normal business hours
of the recipient, if not, then on the next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one day after deposit with a nationally recognized
overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the address as set forth on the signature page hereof or at such other address as such party may designate by ten days’
advance written notice to the other parties hereto. 
 5. Amendments and Waivers. Any term of this Agreement may
be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company, Investor and the Stockholders. Any
amendment or waiver effected in accordance with this Section E.5 shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding (including securities into which such securities are convertible),
each future holder of all such securities and the Company. 
 6. Severability. If one or more provisions of this
Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with
its terms. 
 7. Entire Agreement. This Agreement and the documents referred to herein constitute the entire
agreement among the parties and no party shall be liable or bound to any 

  

 7 

 
other party in any manner by any warranties, representations or covenants except as specifically set forth herein or therein. 
 8. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. 
 [SIGNATURE PAGES FOLLOW] 
  

 8 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

			
	COMPANY:
	
	 CALANDO PHARMACEUTICALS INC.
 a Delaware
corporation

		
	 By:
	 	 /s/ JOHN PETROVICH

		 	 John G. Petrovich
 Chief Executive Officer

  

			
	 Address:
	 	 1710 Flower Avenue, Suite #100
 Duarte, CA 91010
 Fax No. (626) 305-9094

  

			
	INVESTOR:
	
	 ARROWHEAD RESEARCH CORPORATION
 a Delaware corporation

		
	 By:
	 	 /s/ LEON EKCHIAN

		 	 Leon Ekchian
 President

  

			
	 Address:
	 	 201 South Lake Avenue, Suite 703
 Pasadena, CA 91101
 Fax No. (626) 792-5554

 [SIGNATURE PAGE TO COMMON STOCK TRANSFER AGREEMENT] 

	
	STOCKHOLDERS:
	
	 /s/ MARK DAVIS

	 MARK E. DAVIS

	
	 /s/ JOHN G. PETROVICH

	 JOHN G. PETROVICH

	
	 /s/ JOHN ROSSI

	 JOHN ROSSI

 SCHEDULE A 
 SCHEDULE OF STOCKHOLDERS 
  

									
	STOCKHOLDER	  	CALANDO
SHARES SOLD	  	 PURCHASE PRICE
 (CASH)
	  	 PURCHASE PRICE
 (ARC SHARES)*

	Mark E. Davis	  	628,000	  	$	418,667	  	$	837,333
	John G. Petrovich	  	60,000	  	$	40,000	  	$	80,000
	John Rossi	  	120,000	  	$	80,000	  	$	160,000

  

	*	For purposes of determining number of ARC Shares issuable as payment of Purchase Price, an ARC Share shall be valued based on the average of the closing prices of the Common Stock
of Arrowhead Research Corporation during the last ten trading days prior to the Closing. 

  

 2Offer of Employment Letter

 Exhibit 10.1 
  

			
	Mr. Michael Sullivan	 	AVICENA
	15 Forest Street	 	228 Hamilton Ave., 3rd Floor
	Sherborn, MA 01770	 	Palo Alto, CA 94301
		 	(415) 397-2880
		 	Fax: (415) 397-2898

 March 29, 2006 
 RE: Offer of Employment 
 Dear Michael: 
 I am pleased to extend this offer to have you join The Avicena Group, Incorporated, according to the following terms: 
  

			
	 Position:
	  	Vice President of Finance and Chief Financial Officer, Acting
		
	 Reporting to:
	  	CEO, The Avicena Group, Inc.
		
	 Place of Employment:
	  	Cambridge, MA
		
	 Termination:
	  	Either party may terminate the contract, for any reason, with advance written notice of one month.
		
	 Salary and Benefits:
	  	Base Salary: Employee shall be paid a base salary of $90,000.00 subject to applicable federal, state, and local withholding.

 On or before your start date, or on your first day of employment, as a condition of your
employment with the Company, you will be required to sign the Company’s standard Non-Disclosure and Non-Competition Agreement. You represent that you have provided the Company with a copy of all agreements with any current or former employer
concerning restrictions on your right to (a) disclose confidential information, (b) compete with a current or former employer, and/or (c) solicit customers, potential customers and/or employees of a current or former employer. You
represent that you are not bound by any agreement that will prevent or impede you from performing any of the requirements of your position with the Company. 
 If you are agreeable to the above employment offer and conditions please sign and return no later than Friday, March 31, 2006, to my attention c/o The Avicena Group, 228 Hamilton Avenue, 3rd Floor, Palo Alto, CA
94301. 
  

					
	Yours sincerely,	  		 	Agreed to as of: 3/30/06
			
	 /s/ Nasser Menhall
 Nasser
Menhall
 Chairman of the Board
	  		 	 /s/ Michael Sullivan
 Michael
Sullivan
 Employee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]